Holen Sie sich die Stockscreener-App
2.17
3.13%
-0.07
Immix Biopharma Inc Aktie (IMMX) Neueste Nachrichten
Jane Street Group LLC Invests $39,000 in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial - MSN
Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Q3 EPS Estimates for Immix Biopharma Raised by HC Wainwright - Defense World
Immix Biopharma Attends FDA CEO Forum in Washington DC - GlobeNewswire
ImmixBio Joins Elite Pharma Leaders at FDA Commissioner's Strategic Forum on Drug Development - Stock Titan
Immix Biopharma — ASCO/KOL event reaffirms NXC-201’s potential - Smartkarma
HC Wainwright Comments on Immix Biopharma Q1 Earnings - Defense World
Immix Biopharma (NASDAQ:IMMX) Receives Buy Rating from HC Wainwright - Defense World
Immix Biopharma (IMMX) Achieves Significant Clinical Milestone w - GuruFocus
immix biopharma enters at-the-market offering agreement - Investing.com Australia
H.C. Wainwright reaffirms Immix Biopharma stock Buy rating after trial By Investing.com - Investing.com South Africa
H.C. Wainwright reaffirms Immix Biopharma stock Buy rating after trial - Investing.com
Immix Biopharma’s NXC-201 Achieves 70% Complete Response Rate in AL Amyloidosis Trial - Insider Monkey
Immix Biopharma (IMMX) Receives Reiterated 'Buy' Rating from HC - GuruFocus
Immix Biopharma (IMMX) Receives Reiterated 'Buy' Rating from HC Wainwright & Co. | IMMX Stock News - GuruFocus
Immix Biopharma Announces Primary Endpoint Met in positive - GlobeNewswire
Immix Biopharma stock soars to 52-week high of $2.99 By Investing.com - Investing.com India
Immix Biopharma reports high response rate in AL Amyloidosis trial By Investing.com - Investing.com South Africa
immix biopharma enters at-the-market offering agreement By Investing.com - Investing.com South Africa
Immix Biopharma's NXC-201 Trial Meets Primary Endpoint in AL Amyloidosis - MarketScreener
Immix Biopharma stock soars to 52-week high of $2.99 - Investing.com Australia
Immix Biopharma Enters At The Market Offering Agreement - TipRanks
Immix Biopharma reports high response rate in AL Amyloidosis trial - Investing.com
Immix Biopharma Reports 70% Complete Response Rate for NXC-201 in Phase 1/2 AL Amyloidosis Trial at ASCO 2025 - Nasdaq
Immix Biopharma Announces Primary Endpoint Met in positive NXC-201 Interim Results Presented at ... - Eagle-Tribune
Immix Biopharma — Positive newsflow continues for NEXICART-2 - Smartkarma
Immix Biopharma accelerates NEXICART-2 trial enrollment By Investing.com - Investing.com South Africa
Immix Biopharma Further Expands U.S. Clinical Sites for Relapsed/Refractory AL Amyloidosis Trial Nexicart-2 - marketscreener.com
Immix Biopharma (IMMX) Expands NEXICART-2 Trial Sites | IMMX Sto - GuruFocus
Immix Biopharma (IMMX) Expands NEXICART-2 Trial Sites | IMMX Stock News - GuruFocus
Immix Biopharma accelerates NEXICART-2 trial enrollment - Investing.com
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - marketscreener.com
Immix Amyloidosis Trial Surges: 10 New Sites Added, ASCO Data Presentation Coming - Stock Titan
Immix Biopharma (NASDAQ:IMMX) Trading Up 15.3% – Should You Buy? - Defense World
Immix Biopharma reports promising trial results for NXC-201 - Investing.com Australia
Immix Biopharma reports promising trial results for NXC-201 By Investing.com - Investing.com Nigeria
Immix Biopharma Reports Positive ASCO Abstract Results for NXC-201 from NEXICART-2 Trial in Relapsed/Refractory AL Amyloidosis - Nasdaq
Immix Biopharma Announces Positive Results for NXC-201 at - GlobeNewswire
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis - Yahoo Finance
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling ... - Eagle-Tribune
Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis - The Manila Times
Immix Biopharma to Host KOL Event to Discuss NXC-201 - GlobeNewswire
We're Keeping An Eye On Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate - Yahoo Finance
Immix Biopharma — Steady progress in Q125 - Smartkarma
1.11%
1.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):